CIITS in Shenzhen is developing ICVAX® in collaboration with Immuno Cure Group to seek a functional cure beyond current ART limitations.
1 report, 1 independent
Updated May 27
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
CIITS in Shenzhen is developing ICVAX® in collaboration with Immuno Cure Group to seek a functional cure beyond current ART limitations.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Shenzhen
city in China